HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RXST
RxSight, Inc.
RXST lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RXST Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
RXST's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RXST PE Valuation
RXST has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RXST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
RXST has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over RXST on earnings, with more consistent year-over-year improvement.
RXST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.41 |
| Q2 2026 | -$1.13 | -$0.34 |
| Q1 2026 | -$1.13 | -$0.47 |
| Q4 2025 | -$0.95 | -$0.24 |
| Q3 2025 | -$0.87 | -$0.06 |
| Q2 2025 | -$0.79 | +$0.21 |
| Q1 2025 | -$0.66 | +$0.58 |
| Q4 2024 | -$0.71 | +$0.70 |
RXST is still losing money, but far less than before: $1.28 per share over the past year, against $3.19 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RXST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RXST on profitability, with a higher operating margin.
RXST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -19% |
| Q2 2026 | $33.7M | +0.3% |
| Q1 2026 | $30.9M | -18% |
| Q4 2025 | $32.6M | -19% |
| Q3 2025 | $30.3M | -14% |
| Q2 2025 | $33.6M | -3.6% |
| Q1 2025 | $37.9M | +28% |
| Q4 2024 | $40.2M | +41% |
RXST's revenue has slid since its 2024 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -35 points |
| Q2 2026 | -41% | +0.8 points |
| Q1 2026 | -58% | -30 points |
| Q4 2025 | -35% | -13 points |
| Q3 2025 | -40% | -14 points |
| Q2 2025 | -42% | -18 points |
| Q1 2025 | -28% | +8 points |
| Q4 2024 | -21% | +17 points |
RXST's operating margin was −75% last quarter, down 35 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RXST on cash flow, with more consistent year-over-year improvement.
RXST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44M | +$45.8M |
| Q2 2026 | -$11.5M | -$5.6M |
| Q1 2026 | -$11.7M | -$2.2M |
| Q4 2025 | -$2.3M | +$2.9M |
| Q3 2025 | -$1.8M | -$1.3M |
| Q2 2025 | -$5.9M | -$363K |
| Q1 2025 | -$9.4M | +$1.9M |
| Q4 2024 | -$5.1M | +$4.8M |
RXST's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RXST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RXST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +215K shares |
| 1 year | +1.8% | +740K shares |
| 3 years | +17% | +6M shares |
| 5 years | +901% | +37.5M shares |
| Available history | +119% | +22.6M shares |
RXST has 42M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RXST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.5x | Very low |
RXST's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RXST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 22.2 | Neutral |
RXST's weekly RSI is 47 (neutral) and its Stochastic is 22 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RXST PE vs Healthcare Sector
RXST has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RXST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.81 | 12% above |
| 20 week MA | $5.49 | 2% below |
| 50 week MA | $6.88 | 22% below |
| 100 week MA | $11.9 | 55% below |
| 200 week MA | $24.9 | 78% below |
RXST has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RXST on returns for 2026, with the stronger performance.
RXST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.0 | $10.6 | -34% |
| 2022 | $10.6 | $11.9 | +12% |
| 2023 | $11.9 | $40.3 | +239% |
| 2024 | $40.3 | $34.2 | -15% |
| 2025 | $34.2 | $10.9 | -68% |
| 2026 YTD | $10.9 | $5.38 | -51% |
RXST's yearly returns have swung widely, from +239% in 2023 to −68% in 2025. It's down 51% so far in 2026.